ArticleCell research2020
Guiding T lymphopoiesis from pluripotent stem cells by defined transcription factors.
Article in Cell research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 54 citations in OpenAlex.
- Generation of thymus-reconstituting T cell progenitors from human pluripotent stem cells.Cell reports methods · 2026Article
- Generation and functional analysis of melanoma antigen-specific CD8+ T cells derived from S/MAR vector-transfected human induced pluripotent stem cells.International journal of cancer · 2025Article
- Accurate Transcription Factor Activity Inference to Decipher Cell Identity from Single-Cell Transcriptomic Data with MetaTF.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Insights into human melanocyte development and characteristics through pluripotent stem cells combined with single-cell sequencing.iScience · 2025Article
- A single-cell transcriptomic atlas of immune cells in Wilson disease identifies copper-specific immune regulation.iScience · 2025Article
- Conversion of placental hemogenic endothelial cells to hematopoietic stem and progenitor cells.Cell discovery · 2025Article
- Thymosin α1 Combined with PD-1/PD-L1 Inhibitor Plus Chemotherapy in Platinum-Resistant Recurrent Ovarian Cancer : A Retrospective Analysis.Cancer management and research · 2025Article
- Gut Microbiota and Metabolite Changes Induced by Tacrolimus: Implications for Skin Transplant Immunology in Mice.Journal of inflammation research · 2025Article
- Disrupting Notch signaling related HES1 in myeloid cells reinvigorates antitumor T cell responses.Experimental hematology & oncology · 2024Article
- Sensing and guiding cell-state transitions by using genetically encoded endoribonuclease-mediated microRNA sensors.Nature biomedical engineering · 2024Article
- Dysregulated T-cell homeostasis and decreased CD30Heliyon · 2024Article
- A culture method with berbamine, a plant alkaloid, enhances CAR-T cell efficacy through modulating cellular metabolism.Communications biology · 2024Article
- Selecting Monoclonal Cell Lineages from Somatic Reprogramming Using Robotic-Based Spatial-Restricting Structured Flow.Research (Washington, D.C.) · 2024Article
- Updates in novel immunotherapeutic strategies for relapsed/refractory AML.Frontiers in oncology · 2024Review
- Generating hematopoietic cells from human pluripotent stem cells: approaches, progress and challenges.Cell regeneration (London, England) · 2023Review
- Transcription factor Nkx2-3 maintains the self-renewal of hematopoietic stem cells by regulating mitophagy.Leukemia · 2023Article
- Antigen-specific TCR-T cells from Rag2 gene-deleted pluripotent stem cells impede solid tumour growth in a mouse model.Cell proliferation · 2023Article
- Prolonged generation of multi-lineage blood cells in wild-type animals from pluripotent stem cells.Stem cell reports · 2023Article
- Multi-modular structure of the gene regulatory network for specification and commitment of murine T cells.Frontiers in immunology · 2023Review
- Hematopoietic Stem Cells and Regeneration.Cold Spring Harbor perspectives in biology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Achievement of immunocompetent and therapeutic T lymphopoiesis from pluripotent stem cells (PSCs) is a central aim in T cell regenerative medicine. To date, preferentially reconstituting T lymphopoiesis in vivo from PSCs remains a practical challenge. Here we documented that synergistic and transient expression of Runx1 and Hoxa9 restricted in the time window of endothelial-to-hematopoietic transition and hematopoietic maturation stages in a PSC differentiation scheme (iR9-PSC) in vitro induced preferential generation of engraftable hematopoietic progenitors capable of homing to thymus and developing into mature T cells in primary and secondary immunodeficient recipients. Single-cell transcriptome and functional analyses illustrated the cellular trajectory of T lineage induction from PSCs, unveiling the T-lineage specification determined at as early as hemogenic endothelial cell stage and identifying the bona fide pre-thymic progenitors. The induced T cells distributed normally in central and peripheral lymphoid organs and exhibited abundant TCRαβ repertoire. The regenerative T lymphopoiesis restored immune surveillance in immunodeficient mice. Furthermore, gene-edited iR9-PSCs produced tumor-specific T cells in vivo that effectively eradicated tumor cells. This study provides insight into universal generation of functional and therapeutic T cells from the unlimited and editable PSC source.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.